Participants 63 150 5
postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy
Participants 319 425 6
postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy (CRT)
Participants 435 492 13
Four hundred patients with stage II and III rectal cancer
Participants 2092 2117 3
patients with AA genotype
Participants 2446 2499 3
postoperative stage II and III rectal cancer patients
